Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 23, 2007. The document serves as a notification of major interests in shares pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. It details a change in voting rights held by a significant shareholder, Legal & General Group Plc (L&G).
Key Financial Metrics
This filing is a regulatory notification regarding share ownership and does not contain financial performance data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change disclosed is an increase in the voting rights held by Legal & General Group Plc (L&G) in GSK shares:
- Previous Holding: 186,857,268 shares representing 3.05% of voting rights.
- Resulting Holding: 218,457,607 shares representing 3.79% of voting rights.
- Threshold Crossed: The transaction resulted in L&G crossing the 3% voting rights threshold.
- Notification Date: The issuer was notified on February 21, 2007.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a disclosure of shareholding changes under the Disclosure and Transparency Rules (DTR) Sourcebook.
Investor Verification Checklist
- Verify the total number of voting rights outstanding (stated as 5,754,137,998) to confirm the percentage calculations.
- Confirm the breakdown of L&G's holdings between direct and indirect ownership through controlled undertakings (e.g., LGIMH, LGIM, LGAS, LGPL, PMC).
- Check for subsequent filings to track if L&G crosses the 5% threshold, which would trigger additional disclosure requirements.
- Note that this document does not reflect GSK's operational or financial performance for the period.